User Settings
Open AccessArticle

Review of the pharmacotherapy of irritability of autism.

Dean Elbe,Zaahira Lalani-2012-05-01-PubMed
29

TL;DRAbstract

The bulk of positive RCT evidence for the pharmacotherapy of irritability of autism pertains to FDA approved antipsychotics risperidone and aripiprazole. RCTs supporting efficacy of several alternative and adjunctive agents may afford additional treatment options when optimal antipsychotic doses fail to control symptoms or cause intolerable adverse effects. Behavioural therapy should be employed where possible either before, or in addition to pharmacotherapy.

Chat with Paper

AI Agents for this Paper

The bulk of positive RCT evidence for the pharmacotherapy of irritability of autism pertains to FDA approved antipsychotics risperidone and aripiprazole. RCTs supporting efficacy of several alternative and adjunctive agents may afford additional treatment options when optimal antipsychotic doses fail to control symptoms or cause intolerable adverse effects. Behavioural therapy should be employed where possible either before, or in addition to pharmacotherapy.

Keywords

IrritabilityPharmacotherapyAutismMedicinePsychiatryPsychologyAnxiety

Chat

Click to start Chat